Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms. © 2016 International Parkinson and Movement Disorder Society.
Keywords: FDG; PET; Parkinson's disease; acetylcholine; amyloid; atypical parkinsonism; dopamine; serotonin; tau.
© 2016 International Parkinson and Movement Disorder Society.